A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Feb 2, 2015

ASTELLAS BROADENS COMMITMENT TO CLINICAL TRIAL DATA TRANSPARENCY

Tokyo, Feb. 2, 2015—Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) announced today that the company will now make trial data available through www.clinicalstudydatarequest.com, an...

Read more about ASTELLAS BROADENS COMMITMENT TO CLINICAL TRIAL DATA TRANSPARENCY
Jan 30, 2015

Astellas Pharma and Immunomic Therapeutics Announce Exclusive License for JRC2-LAMP-vax, a Vaccine for Japanese Red Cedar Pollinosis

Hershey, PA & Rockville, MD and Tokyo, Japan. January 30, 2015 – Immunomic Therapeutics, Inc. (“Immunomic Therapeutics”), a company developing next generation vaccines based on the LAMP-vax...

Read more about Astellas Pharma and Immunomic Therapeutics Announce Exclusive License for JRC2-LAMP-vax, a Vaccine for Japanese Red Cedar Pollinosis
Jan 23, 2015

ENZALUTAMIDE PHASE 2 TERRAIN TRIAL DEMONSTRATED STATISTICALLY SIGNIFICANT INCREASE IN PFS AS COMPARED TO BICALUTAMIDE IN METASTATIC PROSTATE CANCER

SAN FRANCISCO, CA and TOKYO, JAPAN – January 22, 2015 – Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced topline results from the Phase 2 TERRAIN trial...

Read more about ENZALUTAMIDE PHASE 2 TERRAIN TRIAL DEMONSTRATED STATISTICALLY SIGNIFICANT INCREASE IN PFS AS COMPARED TO BICALUTAMIDE IN METASTATIC PROSTATE CANCER
Jan 23, 2015

Astellas Announces FDA Anti-Infective Drugs Advisory Committee Recommends Approval of CRESEMBA® (isavuconazonium) for Treatment of Invasive Aspergillosis and Mucormycosis

NORTHBROOK, Ill., January 22, 2015, – Astellas today announced that the U.S. Food and Drug Administration’s (FDA) Anti-infective Drugs Advisory Committee voted unanimously to recommend...

Read more about Astellas Announces FDA Anti-Infective Drugs Advisory Committee Recommends Approval of CRESEMBA® (isavuconazonium) for Treatment of Invasive Aspergillosis and Mucormycosis
Jan 22, 2015

ENZALUTAMIDE PHASE 2 TERRAIN TRIAL DEMONSTRATED STATISTICALLY SIGNIFICANT INCREASE IN PFS AS COMPARED TO BICALUTAMIDE IN METASTATIC PROSTATE CANCER

Read more about ENZALUTAMIDE PHASE 2 TERRAIN TRIAL DEMONSTRATED STATISTICALLY SIGNIFICANT INCREASE IN PFS AS COMPARED TO BICALUTAMIDE IN METASTATIC PROSTATE CANCER
Dec 24, 2014

CYTOKINETICS AND ASTELLAS ANNOUNCE EXPANSION OF COLLABORATION FOR DEVELOPMENT OF CK-2127107 IN SPINAL MUSCULAR ATROPHY AND OTHER NEUROMUSCULAR INDICATIONS

Cytokinetics Expects to Receive Over $75 Million in Committed Capital and Reimbursements For Planned Activities

South San Francisco, CA, and Tokyo, December 23, 2014 – Cytokinetics, Incorporated (NASDAQ:CYTK) and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, "Astellas") announced today an amendment to...

Read more about CYTOKINETICS AND ASTELLAS ANNOUNCE EXPANSION OF COLLABORATION FOR DEVELOPMENT OF CK-2127107 IN SPINAL MUSCULAR ATROPHY AND OTHER NEUROMUSCULAR INDICATIONS
Dec 15, 2014

DATA PRESENTED FROM PHASE 2 STUDY OF ENZALUTAMIDE IN ADVANCED ANDROGEN-RECEPTOR POSITIVE, TRIPLE-NEGATIVE BREAST CANCER

SAN FRANCISCO, CA and TOKYO – December 12, 2014 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (Tokyo: 4503), announced today the presentation of Stage 1 and preliminary Stage 2...

Read more about DATA PRESENTED FROM PHASE 2 STUDY OF ENZALUTAMIDE IN ADVANCED ANDROGEN-RECEPTOR POSITIVE, TRIPLE-NEGATIVE BREAST CANCER
Dec 10, 2014

DATA TO BE PRESENTED FROM PHASE 2 STUDY OF ENZALUTAMIDE IN ADVANCED ANDROGEN-RECEPTOR POSITIVE, TRIPLE-NEGATIVE BREAST CANCER

TOKYO, JAPAN – December 10, 2014 – Astellas Pharma Inc. (Tokyo: 4503), announced today that Stage 1 and preliminary Stage 2 data from a Phase 2 study evaluating the use of enzalutamide as a...

Read more about DATA TO BE PRESENTED FROM PHASE 2 STUDY OF ENZALUTAMIDE IN ADVANCED ANDROGEN-RECEPTOR POSITIVE, TRIPLE-NEGATIVE BREAST CANCER
Dec 10, 2014

Our Challenge for Innovative Drug

Read more about Our Challenge for Innovative Drug
Dec 9, 2014

Astellas Named to FTSE4Good Sustainability Index for the Third Year

Tokyo, Dec. 9, 2014 – Astellas Pharma Inc. (TSE: 4503; Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) announced that it has been selected for the third year to be included in the...

Read more about Astellas Named to FTSE4Good Sustainability Index for the Third Year

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts